{"id":9665,"date":"2026-03-18T11:12:29","date_gmt":"2026-03-18T03:12:29","guid":{"rendered":"https:\/\/regask.com\/?p=9665"},"modified":"2026-03-18T11:12:29","modified_gmt":"2026-03-18T03:12:29","slug":"die-ema-eroffnet-die-bewerbungsphase-fur-portfolio-und-technologietreffen-2026-fur-grose-pharmaunternehmen","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","title":{"rendered":"EMA er\u00f6ffnet Antragsphase f\u00fcr Portfolio und Technologie 2026\u2026"},"content":{"rendered":"<p><span data-contrast=\"auto\">An\u00a0<\/span><b><span data-contrast=\"auto\">10. M\u00e4rz 2026<\/span><\/b><span data-contrast=\"auto\">, Die\u00a0<\/span><b><span data-contrast=\"auto\">Europ\u00e4ische Arzneimittel-Agentur (EMA)<\/span><\/b><span data-contrast=\"auto\">\u00a0gab bekannt, dass die Bewerbungsphase nun er\u00f6ffnet ist f\u00fcr\u00a0<\/span><b><span data-contrast=\"auto\">Portfolio- und Technologie-Meetings (PTMs)<\/span><\/b><span data-contrast=\"auto\">\u00a0geplant f\u00fcr die\u00a0<\/span><b><span data-contrast=\"auto\">zweite H\u00e4lfte des Jahres 2026<\/span><\/b><span data-contrast=\"auto\">. Das Programm l\u00e4dt ein\u00a0<\/span><b><span data-contrast=\"auto\">gro\u00dfe Pharmaunternehmen mit umfangreichen Portfolios an Arzneimitteln<\/span><\/b><span data-contrast=\"auto\">\u00a0um strukturierte Gespr\u00e4che mit der Beh\u00f6rde zu f\u00fchren.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Diese\u00a0<\/span><b><span data-contrast=\"auto\">virtuelle, kostenlose Treffen<\/span><\/b><span data-contrast=\"auto\">\u00a0sind darauf ausgelegt,\u00a0<\/span><b><span data-contrast=\"auto\">Herausforderungen bei der Entwicklung des Produktportfolios<\/span><\/b><span data-contrast=\"auto\">, erfassen\u00a0<\/span><b><span data-contrast=\"auto\">aufkommende und disruptive Technologien<\/span><\/b><span data-contrast=\"auto\">, und der EMA helfen, die\u00a0<\/span><b><span data-contrast=\"auto\">F\u00fcr zuk\u00fcnftige Antr\u00e4ge auf Marktzulassung ist wissenschaftliches und regulatorisches Fachwissen erforderlich.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Unternehmen, die an einer Teilnahme interessiert sind, m\u00fcssen die festgelegten Unterlagen einreichen.\u00a0<\/span><b><span data-contrast=\"auto\">PTM-Antragsformular bis zum 30. April 2026<\/span><\/b><span data-contrast=\"auto\">.Die EMA wird die eingereichten Unterlagen pr\u00fcfen und die Antragsteller \u00fcber das Ergebnis informieren.\u00a0<\/span><b><span data-contrast=\"auto\">bis Ende Mai 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><\/p>\n<div class=\"row\"  id=\"row-81054867\">\n\n\t<div id=\"col-175304377\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n\t<div id=\"gap-1562706499\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1562706499 {\n  padding-top: 20px;\n}\n<\/style>\n\t<\/div>\n\t\n<h2>Details zum Update<\/h2>\n\t<div id=\"gap-1296175583\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1296175583 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Der\u00a0<\/span><b><span data-contrast=\"auto\">Portfolio- und Technologie-Meetings (PTMs)<\/span><\/b><span data-contrast=\"auto\">\u00a0bietet gro\u00dfen Pharmaunternehmen die M\u00f6glichkeit zum Austausch\u00a0<\/span><b><span data-contrast=\"auto\">regulatorische und wissenschaftliche \u00dcberlegungen f\u00fcr das gesamte Portfolio<\/span><\/b><span data-contrast=\"auto\">\u00a0direkt mit der EMA. Die Treffen werden durchgef\u00fchrt\u00a0<\/span><b><span data-contrast=\"auto\">praktisch und kostenlos f\u00fcr die Antragsteller<\/span><\/b><span data-contrast=\"auto\">, wodurch die Teilnahmebarrieren gesenkt und gleichzeitig ein strategisches Engagement erm\u00f6glicht werden.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Das Programm wurde speziell entwickelt, um dabei zu helfen,\u00a0<\/span><b><span data-contrast=\"auto\">Probleme, die den Fortschritt des Produktportfolios beeintr\u00e4chtigen<\/span><\/b><span data-contrast=\"auto\">\u00a0und den Dialog dar\u00fcber erleichtern\u00a0<\/span><b><span data-contrast=\"auto\">innovative und bahnbrechende Technologien<\/span><\/b><span data-contrast=\"auto\">\u00a0die k\u00fcnftige regulatorische Bewertungen beeinflussen k\u00f6nnten. Durch diese Diskussionen will die EMA ihre\u00a0<\/span><b><span data-contrast=\"auto\">wissenschaftliche und regulatorische Kompetenzen<\/span><\/b><span data-contrast=\"auto\">\u00a0mit den sich wandelnden Bed\u00fcrfnissen der Industriepipelines.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Wird einem Besprechungsantrag stattgegeben, m\u00fcssen die Antragsteller Folgendes einreichen:\u00a0<\/span><b><span data-contrast=\"auto\">ausgef\u00fclltes Briefing-Dokument<\/span><\/b><span data-contrast=\"auto\">\u00a0unter Verwendung der\u00a0<\/span><b><span data-contrast=\"auto\">Vorlage der EMA (Referenznummer: EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">. Dieses Dokument muss zugestellt werden\u00a0<\/span><b><span data-contrast=\"auto\">vier bis sechs Wochen vor dem geplanten Treffen \u00fcber Eudralink<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Dar\u00fcber hinaus m\u00fcssen die Bewerber Folgendes einreichen:\u00a0<\/span><b><span data-contrast=\"auto\">Vorbesprechung und Teilnehmerliste eine Woche vor dem Besprechungstermin<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-175304377 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-53576938\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Feedback-Frist<\/h2>\n\t<div id=\"gap-308699569\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-308699569 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Der\u00a0<\/span><b><span data-contrast=\"auto\">Die Frist f\u00fcr die Einreichung des Antragsformulars f\u00fcr das Portfolio- und Technologietreffen endet am 30. April 2026.<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Der\u00a0<\/span><b><span data-contrast=\"auto\">Die Europ\u00e4ische Arzneimittel-Agentur wird die Ergebnisse der Antr\u00e4ge und die n\u00e4chsten Schritte bis Ende Mai 2026 mitteilen.<\/span><\/b><span data-contrast=\"auto\">, wobei genehmigte Treffen w\u00e4hrend des\u00a0<\/span><b><span data-contrast=\"auto\">zweite H\u00e4lfte des Jahres 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-53576938 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1013605683\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>Warum es wichtig ist<\/h2>\n\t<div id=\"gap-559865901\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-559865901 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Der\u00a0<\/span><b><span data-contrast=\"auto\">PTM-Programm<\/span><\/b><span data-contrast=\"auto\">\u00a0bietet Unternehmen mit\u00a0<\/span><b><span data-contrast=\"auto\">gro\u00dfe Pipelines f\u00fcr Arzneimittel<\/span><\/b><span data-contrast=\"auto\">\u00a0um\u00a0<\/span><b><span data-contrast=\"auto\">Herausforderungen bei der portfolio\u00fcbergreifenden Entwicklung und neue Technologien<\/span><\/b><span data-contrast=\"auto\">\u00a0mit den Regulierungsbeh\u00f6rden in einem fr\u00fchen Stadium.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Durch die Erm\u00f6glichung eines fr\u00fchzeitigen Dialogs unterst\u00fctzt die Initiative\u00a0<\/span><b><span data-contrast=\"auto\">proaktive Regulierungsstrategie<\/span><\/b><span data-contrast=\"auto\">, verbessert\u00a0<\/span><b><span data-contrast=\"auto\">\u00dcbereinstimmung hinsichtlich wissenschaftlicher Erwartungen<\/span><\/b><span data-contrast=\"auto\">, und tr\u00e4gt zur Reduzierung bei\u00a0<\/span><b><span data-contrast=\"auto\">k\u00fcnftige regulatorische Unsicherheit<\/span><\/b><span data-contrast=\"auto\">\u00a0\u00fcber komplexe Portfolios hinweg, einschlie\u00dflich\u00a0<\/span><b><span data-contrast=\"auto\">neuartige Modalit\u00e4ten, Biologika und fortschrittliche Therapien<\/span><\/b><span data-contrast=\"auto\">. Der\u00a0<\/span><b><span data-contrast=\"auto\">virtuelles und kostenloses Format<\/span><\/b><span data-contrast=\"auto\">\u00a0verbessert die Zug\u00e4nglichkeit f\u00fcr qualifizierte Organisationen zus\u00e4tzlich.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1013605683 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-717880822\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>F\u00fcr wen ist das relevant?<\/h2>\n\t<div id=\"gap-1803768707\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1803768707 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Diese Ank\u00fcndigung ist besonders relevant f\u00fcr <strong>Teams f\u00fcr Zulassungsangelegenheiten, medizinische Angelegenheiten, Forschung und Entwicklung sowie Vertrieb<\/strong> innerhalb von Pharmaunternehmen im Management <strong>gro\u00dfe Portfolios von Arzneimitteln<\/strong>. Diese Funktionen spielen eine Schl\u00fcsselrolle bei der Vorbereitung von PTM-Antr\u00e4gen, der Identifizierung portfolio\u00fcbergreifender Fragestellungen und der Koordination von Briefing-Unterlagen, die wissenschaftliche, regulatorische und strategische Pipeline-\u00dcberlegungen ber\u00fccksichtigen.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-717880822 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-660224144\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h2>N\u00e4chste Schritte<\/h2>\n\t<div id=\"gap-1231980573\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1231980573 {\n  padding-top: 15px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span data-contrast=\"auto\">Organisationen, die eine Teilnahme planen, sollten fr\u00fchzeitig mit der internen Koordination beginnen, um eine rechtzeitige Vorbereitung und Einreichung der Unterlagen zu gew\u00e4hrleisten.\u00a0<\/span><b><span data-contrast=\"auto\">Anmeldeformular f\u00fcr das Portfolio- und Technologietreffen (PTM) bis zum 30. April 2026<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Teams f\u00fcr regulatorische Angelegenheiten<\/span><\/b><span data-contrast=\"auto\">\u00a0sollte zun\u00e4chst beurteilen\u00a0<\/span><b><span data-contrast=\"auto\">Portfolio-Berechtigung<\/span><\/b><span data-contrast=\"auto\">, vervollst\u00e4ndigen und einreichen\u00a0<\/span><b><span data-contrast=\"auto\">PTM-Anwendung<\/span><\/b><span data-contrast=\"auto\">, und falls der Besprechungsantrag genehmigt wird, die Vorbereitung der\u00a0<\/span><b><span data-contrast=\"auto\">EMA-Briefing-Dokument (EMA\/571070\/2023)<\/span><\/b><span data-contrast=\"auto\">\u00a0und verwalten\u00a0<\/span><b><span data-contrast=\"auto\">Eudralink-Einreichung vier bis sechs Wochen vor dem geplanten Treffen<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"2\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Medical Affairs Teams<\/span><\/b><span data-contrast=\"auto\">\u00a0sollte identifiziert\u00a0<\/span><b><span data-contrast=\"auto\">Portfolio\u00fcbergreifende wissenschaftliche und Entwicklungsfragen<\/span><\/b><span data-contrast=\"auto\">\u00a0dies erfordern k\u00f6nnte, und eine enge Zusammenarbeit mit der Abteilung f\u00fcr regulatorische Angelegenheiten, um die\u00a0<\/span><b><span data-contrast=\"auto\">Tagesordnung und Briefing-Informationen<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"3\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Forschungs- und Entwicklungsteams<\/span><\/b><span data-contrast=\"auto\">\u00a0sollte beitragen\u00a0<\/span><b><span data-contrast=\"auto\">zu Pipeline-Daten und technologiebezogenen Themen<\/span><\/b><span data-contrast=\"auto\">, einschlie\u00dflich\u00a0<\/span><b><span data-contrast=\"auto\">neuartige oder disruptive Modalit\u00e4ten<\/span><\/b><span data-contrast=\"auto\">, zur Aufnahme in die\u00a0<\/span><b><span data-contrast=\"auto\">Briefing-Dokument und Pr\u00e4sentation vor dem Treffen<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<ul>\n<li aria-setsize=\"-1\" data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559683&quot;:0,&quot;335559684&quot;:-2,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:&#091;8226&#093;,&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" data-aria-posinset=\"4\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Vertriebs- und Marketingteams<\/span><\/b><span data-contrast=\"auto\">\u00a0sollte Input geben\u00a0<\/span><b><span data-contrast=\"auto\">Priorit\u00e4ten der Portfoliostrategie und des Lebenszyklusmanagements<\/span><\/b><span data-contrast=\"auto\">\u00a0die davon profitieren k\u00f6nnten\u00a0<\/span><b><span data-contrast=\"auto\">fr\u00fche wissenschaftliche Abstimmung mit der Europ\u00e4ischen Arzneimittel-Agentur<\/span><\/b><span data-contrast=\"auto\">.<\/span><span data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><b><span data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/de\/\">RegASK<\/a>\u00a0ist eine f\u00fchrende agentenbasierte KI-Plattform f\u00fcr regulatorische Intelligenz und Workflow-Orchestrierung<\/span><\/b><span data-contrast=\"auto\">\u00a0das globale Organisationen in stark regulierten Sektoren, darunter Konsumg\u00fcter und Biowissenschaften, in die Lage versetzt, sich proaktiv in komplexen regulatorischen Umfeldern zu bewegen. Durch die Kombination\u00a0<\/span><b><span data-contrast=\"auto\">fortschrittliche Agenten-KI mit Experten im Regelkreis<\/span><\/b><span data-contrast=\"auto\">,\u00a0<a href=\"http:\/\/regask.com\/de\/\">RegASK<\/a>\u00a0liefert\u00a0<\/span><b><span data-contrast=\"auto\">zeitnahe, vorausschauende und umsetzbare Erkenntnisse sowie durchg\u00e4ngige Automatisierung<\/span><\/b><span data-contrast=\"auto\">, Wir unterst\u00fctzen Teams bei der Verfolgung regulatorischer Initiativen wie EMA-Engagement-Programmen, der effizienten Dokumentationserstellung und der Optimierung der Compliance in mehr als\u00a0<\/span><b><span data-contrast=\"auto\">160 L\u00e4nder<\/span><\/b><span data-contrast=\"auto\">. <a href=\"http:\/\/regask.com\/de\/\"><strong>Mehr erfahren <\/strong><\/a>oder<a href=\"https:\/\/regask.com\/de\/demo-buchen\/\"><strong> Jetzt Demo buchen.<\/strong><\/a><\/span><strong>\u00a0<\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-660224144 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>\n<div class=\"row\"  id=\"row-627119509\">\n\n\t<div id=\"col-1475087443\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<div class=\"is-divider divider clearfix\" style=\"margin-top:2em;margin-bottom:2em;max-width:20%;height:1px;background-color:#a5acd9;\"><\/div>\n<h3>FAQs<\/h3>\n\t<div id=\"gap-1097404335\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1097404335 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<h4><span class=\"TextRun MacChromeBold SCXW267956491 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW267956491 BCX0\" data-ccp-parastyle=\"heading 3\">Was besagt die neue CDE-Leitlinie zu klinischen Studien mit Grippeimpfstoffen?<\/span><\/span><span class=\"EOP SCXW267956491 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-2017498826\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-2017498826 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><strong>Portfolio- und Technologie-Meetings (PTMs)<\/strong> sind strukturierte virtuelle Meetings, die von der <strong>Europ\u00e4ische Arzneimittel-Agentur<\/strong> um gro\u00dfen Pharmaunternehmen die M\u00f6glichkeit zu geben, zu diskutieren <strong>Herausforderungen bei der Entwicklung des Produktportfolios und neue Technologien<\/strong> mit der Regulierungsbeh\u00f6rde.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1475087443 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1081054317\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW184197477 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW184197477 BCX0\" data-ccp-parastyle=\"heading 3\">Wer kann sich f\u00fcr die EMA Portfolio- und Technologie-Meetings bewerben?<\/span><\/span><span class=\"EOP SCXW184197477 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1020873954\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1020873954 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Das PTM-Programm steht offen f\u00fcr <strong>gro\u00dfe Pharmaunternehmen mit umfangreichen Produktportfolios an Arzneimitteln.<\/strong> Antragsberechtigte Unternehmen m\u00fcssen ein Antragsformular zur Pr\u00fcfung bei der EMA einreichen.<\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1081054317 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-682772113\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW3460145 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW3460145 BCX0\" data-ccp-parastyle=\"heading 3\">Wann ist die Bewerbungsfrist f\u00fcr ein PTM im Jahr 2026?<\/span><\/span><span class=\"EOP SCXW3460145 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1862663744\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1862663744 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p>Der <strong>Bewerbungsschluss ist der 30. April 2026.<\/strong> Der <strong>Die EMA wird die Ergebnisse der Antr\u00e4ge bis Ende Mai 2026 mitteilen.,<\/strong> und genehmigte Treffen finden statt in <strong>zweite Jahresh\u00e4lfte 2026. <\/strong><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-682772113 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n\n\t<div id=\"col-1357397484\" class=\"col small-12 large-12\"  >\n\t\t\t\t<div class=\"col-inner\"  >\n\t\t\t\n\t\t\t\n<h4><span class=\"TextRun MacChromeBold SCXW14904628 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">Wie kann\u00a0<\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">RegASK<\/span><span class=\"NormalTextRun SCXW14904628 BCX0\" data-ccp-parastyle=\"heading 3\">\u00a0Wie k\u00f6nnen Organisationen solche Aktualisierungen verwalten?<\/span><\/span><span class=\"EOP SCXW14904628 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;134245418&quot;:true,&quot;134245529&quot;:true,&quot;335559738&quot;:281,&quot;335559739&quot;:281}\">\u00a0<\/span><\/h4>\n\t<div id=\"gap-1738654491\" class=\"gap-element clearfix\" style=\"display:block; height:auto;\">\n\t\t\n<style>\n#gap-1738654491 {\n  padding-top: 10px;\n}\n<\/style>\n\t<\/div>\n\t\n<p><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><a href=\"http:\/\/regask.com\/de\/\"><strong><span class=\"NormalTextRun SpellingErrorV2Themed SCXW253285960 BCX0\">RegASKs<\/span><\/strong><\/a><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0<strong>agentic KI-Plattform f\u00fcr regulatorische Intelligenz<\/strong><\/span><\/span><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">hilft Pharmaunternehmen\u00a0<\/span><\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">Monitor<\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">Globale regulatorische Ank\u00fcndigungen, Beteiligungsm\u00f6glichkeiten und Konsultationsprogramme<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0in Echtzeit. Dies erm\u00f6glicht es den Regulierungsbeh\u00f6rden,\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">identifizieren<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0Initiativen wie zum Beispiel\u00a0<\/span><\/span><strong><span class=\"TextRun MacChromeBold SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\">EMA-Portfolio- und Technologietreffen<\/span><\/span><\/strong><span class=\"TextRun SCXW253285960 BCX0\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"auto\"><span class=\"NormalTextRun SCXW253285960 BCX0\"><strong>,<\/strong> interne Vorbereitung koordinieren und\u00a0<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">pflegen<\/span><span class=\"NormalTextRun SCXW253285960 BCX0\">\u00a0Bereitschaft zur Einhaltung von Vorschriften in komplexen globalen Pipelines.<\/span><\/span><span class=\"EOP SCXW253285960 BCX0\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:false,&quot;335559738&quot;:240,&quot;335559739&quot;:240}\">\u00a0<\/span><\/p>\n\t\t<\/div>\n\t\t\t\t\n<style>\n#col-1357397484 > .col-inner {\n  margin: 0px 0px -20px 0px;\n}\n<\/style>\n\t<\/div>\n\n\t\n<\/div>","protected":false},"excerpt":{"rendered":"<p>On\u00a0March 10, 2026, the\u00a0European Medicines Agency (EMA)\u00a0announced that applications are now open for\u00a0Portfolio and Technology Meetings (PTMs)\u00a0scheduled for the\u00a0second half of 2026. The program invites\u00a0large pharmaceutical companies with extensive medicinal product portfolios\u00a0to engage in structured discussions with the agency.\u00a0 These\u00a0virtual, free-of-charge meetings\u00a0are designed to address\u00a0product portfolio development challenges, capture\u00a0emerging and disruptive technologies, and help the&#8230;<\/p>","protected":false},"author":43,"featured_media":9666,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33,538,35],"tags":[],"class_list":["post-9665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-european-union","category-pharma-biotech-latest-insights"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EMA Opens Applications for 2026 Portfolio Meetings<\/title>\n<meta name=\"description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/die-ema-eroffnet-die-bewerbungsphase-fur-portfolio-und-technologietreffen-2026-fur-grose-pharmaunternehmen\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies\" \/>\n<meta property=\"og:description\" content=\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/die-ema-eroffnet-die-bewerbungsphase-fur-portfolio-und-technologietreffen-2026-fur-grose-pharmaunternehmen\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T03:12:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"},\"wordCount\":1002,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"articleSection\":[\"Regulatory News\",\"European Union\",\"Pharma and Biotech\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\",\"name\":\"EMA Opens Applications for 2026 Portfolio Meetings\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"datePublished\":\"2026-03-18T03:12:29+00:00\",\"description\":\"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png\",\"width\":800,\"height\":600,\"caption\":\"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EMA nimmt Bewerbungen f\u00fcr Portfolio-Meetings 2026 entgegen","description":"Die EMA nimmt ab sofort Bewerbungen f\u00fcr die Portfolio- und Technologiegespr\u00e4che 2026 f\u00fcr gro\u00dfe Pharmaunternehmen entgegen. Bewerbungsschluss ist der 30. April.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/die-ema-eroffnet-die-bewerbungsphase-fur-portfolio-und-technologietreffen-2026-fur-grose-pharmaunternehmen\/","og_locale":"de_DE","og_type":"article","og_title":"EMA Opens Applications for 2026 Portfolio and Technology Meetings for Large Pharmaceutical Companies","og_description":"The EMA opens applications for 2026 Portfolio and Technology Meetings for large pharmaceutical companies. Apply by April 30.","og_url":"https:\/\/regask.com\/de\/die-ema-eroffnet-die-bewerbungsphase-fur-portfolio-und-technologietreffen-2026-fur-grose-pharmaunternehmen\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2026-03-18T03:12:29+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"5\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#article","isPartOf":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"EMA Opens Applications for 2026 Portfolio and Technolog&hellip;","datePublished":"2026-03-18T03:12:29+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"},"wordCount":1002,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","articleSection":["Regulatory News","European Union","Pharma and Biotech"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","url":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/","name":"EMA nimmt Bewerbungen f\u00fcr Portfolio-Meetings 2026 entgegen","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","datePublished":"2026-03-18T03:12:29+00:00","description":"Die EMA nimmt ab sofort Bewerbungen f\u00fcr die Portfolio- und Technologiegespr\u00e4che 2026 f\u00fcr gro\u00dfe Pharmaunternehmen entgegen. Bewerbungsschluss ist der 30. April.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/ema-opens-applications-for-2026-portfolio-and-technology-meetings-for-large-pharmaceutical-companies\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2026\/03\/ema-opens-applications-2026-portfolio-technology-meetings-large-pharmaceutical-companies.png","width":800,"height":600,"caption":"Ema Opens Applications 2026 Portfolio Technology Meetings Large Pharmaceutical Companies"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Das regulatorische KI-Betriebssystem f\u00fcr leistungsstarke Teams","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/9665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=9665"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/9665\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/9666"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=9665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=9665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=9665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}